Global Fortune 200 Pharmaceutical Company Selects Candelis ASTRA Image Exchange Platform for Clinical Trials and Data Sharing

Newport Beach, CA (June 19, 2015) – Candelis, Inc., one of the fastest growing healthcare IT companies, announces that its ASTRATM image exchange platform has been adopted by a Fortune 200 pharmaceutical company for worldwide clinical trials image and data sharing.

Clinical trial protocols require that studies are performed with specific imaging requirements, often resulting in a voluminous collection of data. Clinical trials involving imaging can range from simple trials with a few dozen subjects to those that are large and complex with thousands of subjects requiring hundreds of gigabytes of storage space.

“Although the pharmaceutical company explored other software options, we were able to customize ASTRATM Plus to present the clinical trial images using a hierarchy of clinical trials, subjects, visits and DICOM series. This organizational hierarchy made the Candelis solution the best fit for their needs,” said Tricia Buenvenida, Director of Marketing for Candelis.

“Historically, pharma companies conducting the clinical trials would store their images on portable media and ship that media, resulting in additional time and costs,” explains Ms. Buenvenida. “With the Candelis’ ASTRATM Plus infrastructure, the pharmaceutical company found an alternative solution to optimize the image exchange process and eliminate the hassle.”

ASTRATM Plus also provides an effective distribution channel to send the images in a batch mode so that analysis partners can safely open and download large amounts of data without the need for user IDs, firewall rules, specialized software and VPN accounts.

ASTRATM Plus is tailored for clinical trials, a feature that fits the operational needs of the pharmaceutical company. With Group 12 DICOM fields, collation of clinical trial objects are made possible. Side-by-side visualization and policy-based anonymization are part of the comprehensive services offered by ASTRATM Plus.

While it is not our policy to disclose the names of our customers publicly, the customer is one of our references and can be made available to qualified prospects to provide feedback,” clarified Ms. Buenvenida.